Roche and Zealand Pharma's Obesity Drug Candidate: A Dual Approach

Roche Holding and Zealand Pharma are collaborating on an obesity drug candidate known as petrelintide. Recent insights from Citi analysts suggest that the drug may have enhanced prospects when used in combination with another Roche candidate, CT-388, rather than as a standalone treatment. This conclusion follows results from a midstage clinical trial, which indicated that while petrelintide's efficacy was underwhelming, its tolerability profile resembled that of a placebo.

Wall Street Journal

The midstage clinical trial results revealed that petrelintide did not meet efficacy expectations. However, the tolerability profile could be advantageous when combined with CT-388. Citi analysts emphasize that this combination approach may yield better outcomes than administering petrelintide alone. A late-stage study for petrelintide as a monotherapy is scheduled to commence in the latter half of the year, alongside a midstage trial for the combination therapy.

Wall Street Journal

The potential for a combination therapy involving petrelintide and CT-388 could signify a shift in the treatment paradigm for obesity. If successful, this dual approach may offer a more effective solution for patients struggling with obesity, addressing both efficacy and tolerability concerns that have plagued standalone therapies.

Wall Street Journal

Citi analysts have articulated that the combination of petrelintide and CT-388 holds greater promise than either drug used independently. This perspective aligns with the ongoing trend in the pharmaceutical industry to explore combination therapies to enhance treatment efficacy.

Wall Street Journal

While the combination therapy approach is viewed positively by some analysts, there may be skepticism regarding the initial underperformance of petrelintide in clinical trials. Critics may argue that reliance on combination therapies could overshadow the need for developing more effective standalone treatments.

Wall Street Journal

The upcoming late-stage study for petrelintide as a monotherapy and the midstage trial for the combination therapy are critical next steps in determining the viability of these treatments in the obesity market. The outcomes of these trials will be pivotal in shaping future strategies for Roche and Zealand Pharma in addressing obesity.

Wall Street Journal

• “The combination has greater potential, the analysts say.” — Citi Analysts

Wall Street Journal